Osteoporosis: Differences and Similarities in Male and Female Patients

Orthopedic Clinics of North America

Volumn 37, Issue 4, 2006, Pages 601-609

  Lane, Joseph Michael ^a,b   Serota, Alana Carey ^b   Raphael, Bradley ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; VITAMIN D;

ANATOMY; ANDROGEN DEFICIENCY; BONE DENSITY; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEMENTIA; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BINDING; DRUG METABOLISM; DRUG PULSE THERAPY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FRACTURE; FRAGILITY FRACTURE; HALF LIFE TIME; HEART INFARCTION; HOT FLUSH; HUMAN; INCIDENCE; INDIGESTION; MENOPAUSAL SYNDROME; MONOTHERAPY; MORTALITY; NEPHROLITHIASIS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SECONDARY OSTEOPOROSIS; SEX DIFFERENCE; UTERUS CANCER; VAGINAL DRYNESS; VITAMIN D DEFICIENCY;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESTROGENS; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; INCIDENCE; MALE; OSTEOPOROSIS; RISK FACTORS; SEX CHARACTERISTICS; SEX FACTORS; TENSILE STRENGTH; TERIPARATIDE;

EID: 33751425097     PISSN: 00305898     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ocl.2006.09.002     Document Type: Review

References (50)

1. Genant H.K., Cooper C., Poor G., et al. Interim report and recommendations of the World Health Organization Task Force for Osteoporosis. Osteoporos Int 10 4 (2001) 259-264
2. Hannan M.T., Felson D.T., et al. Bone mineral density in elderly men and women: results from the Framingham osteoporosis study. J Bone Miner Res 7 5 (1997) 547-553
3. Jones G., Nguyen T., Sambrook P., et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 309 6956 (1994) 691-695
4. Khosla S., Melton III L.J., et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83 7 (1998) 2266-2274
5. Cummings S.R., Black D.M., et al. Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group. Lancet 341 8837 (1993) 72-75
6. Riggs B.L., and Melton III L.J. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17 5 Suppl (1995) 505S-511S
7. Melton L.J., Chrischilles E.A., Cooper C., et al. How many women have osteoporosis?. J Bone Miner Res 7 (2005) 1005-1010
8. Gullberg B., Johnell O., et al. World-wide projections for hip fracture. Osteoporos Int 7 5 (1997) 407-413
9. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral factures during treatment with antiresorptive drugs. Am J Med 112 4 (2002) 281-289
10. Chang K.P., Center J.R., et al. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 19 4 (2004) 532-536
11. Cooper C., Campion G., et al. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2 6 (1992) 285-289
12. Gilsanz V. Accumulation of bone mass during childhood and adolescence. In: Orwoll E.S. (Ed). Osteoporosis in men (1999), Academic, San Diego (CA) 65-85
13. Delaney M.F. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 194 2 Suppl (2006) S12-S23
14. Seeman E. Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86 (2001) 4576-4584
15. Campion J., and Maricic M.J. Osteoporosis in men. Am Fam Physician 67 7 (2003) 1521-1526
16. Nguyen T.V., Eisman J.A., et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144 3 (1996) 255-263
17. Seeman E., Melton III L.J., O'Fallon W.M., and Riggs B.L. Risk factors for spinal osteoporosis in men. Am J Med 75 (1983) 977-983
18. Lindsay R., Silverman S.L., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285 3 (2001) 320-323
19. Lin J.T., and Lane J.M. Osteoporosis: a review. Clin Orthop Relat Res 425 (2002) 126-134
20. Van Der Klift M., De Laet C.E.D.H., et al. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 17 6 (2001) 1051-1056
21. de Laet C.E., van der Klift M., et al. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17 12 (2002) 2231-2236
22. Orwoll E.S. Assessing bone density in men. J Bone Miner Res 15 10 (2000) 1867-1870
23. Melton L.J., Orwoll E.S., et al. Does bone density predict fractures comparably in men and women?. Osteoporos Int 12 9 (2001) 707-709
24. Gillespie L.D., Gillespie W.J., Robertson M.C., et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 4 (2003) CD000340
25. Parker M.J., Gillespie W.J., and Gillespie L.D. Effectiveness of hip protectors for preventing hip fractures in elderly people: a systematic review. BMJ 332 7541 (2006) 571-574
26. Baim S., Wilson C.R., Lewiecki E.M., et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8 4 (2005) 371-378
27. Orwoll E.S. Osteoporosis in men. Endocrinol Metab Clin North Am 27 (1998) 349-367
28. Miller P.D., Baran D.T., Bilezikian J.P., et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2 (1999) 323-380
29. Chapuy M.D., Arlot M.E., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327 23 (1992) 1637-1642
30. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clinic Proc 81 3 (2006) 353-373
31. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and risk of fractures. N Engl J Med 354 7 (2006) 669-683
32. Rossouw J.E., Anderson G.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
33. LaCroix A.Z. Estrogen with and without progestin: benefits and risks of short-term use. Am J Med 118 12 Suppl. 2 (2005) 79-87
34. Maricic M., Adachi J.D., et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162 10 (2002) 1140-1143
35. Black D.M., Greenspan S.L., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 13 (2003) 1207-1215
36. Ring J.D., Orwoll E.S., et al. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13 3 (2002) 195-199
37. Odvina C.V., Zerwekh J.E., Rae D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 900 3 (2005) 1897-1899
38. Agarwala S., Jain D., Joshi V.R., et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVEN of the hip: a prospective open-label study. Rheumatology (Oxford) 44 3 (2005) 352-359
39. Chestnut III C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109 4 (2000) 267-276
40. Ofluoglu D., Akyuz G., Unay O., et al. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol (2006)
41. Dempster D.W., Cosman F., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16 10 (2001) 1846-1853
42. Neer R.M., Arnaud C.D., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 19 (2001) 1434-1441
43. Body J.J., Gaich G.A., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 10 (2002) 4528-4535
44. Kurland E.S., Heller S.L., Diamond B., et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide. Osteoporosis Int 15 12 (2004) 992-997
45. Finkelstein J.S., Hayes A., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 13 (2002) 1216-1226
46. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353 6 (2005) 566-575
47. Ste-Marie L.G., Schwartz S.L., Hossain A., et al. Effect of teriparatide on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21 2 (2006) 283-291
48. Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20 11 (2005) 1905-1911
49. Alkhiary Y.M., Gerstenfeld L.C., Krall E., et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone. J Bone Joint Surg Am 87 4 (2005) 731-741
50. Indications and reporting for dual-energy x-ray absorptiometry. J Clin Densitom 7 (2004) 37